[email protected]

Cost-effectiveness analysis of pembrolizumab plus standard

Conclusion:In patients with metastatic non-squamous NSCLC, pembrolizumab plus standard chemotherapy of platinum and pemetrexed as the first-line treatment is not cost-effective in China, regardless of TPS. First-Line Pembrolizumab Plus Chemotherapy for Patients

  • BackgroundMethodsResultsConclusionsEditorial AcknowledgementDisclosurePembrolizumab (pembro) + carboplatin and paclitaxel/nab-paclitaxel significantly improved OS and PFS vs placebo in patients (pts) with previously untreated stage IV squamous NSCLC in the phase III KEYNOTE-407 study (NCT02775435). At protocol-specified final analysis (data cutoff May 9, 2019), HR for OS was 0.71 (95% CI, 0.580.88). We report long-term data and outcomes for pts who completed 35 cycles (2 y) of treatment.Pembrolizumab plus cetuximab in patients with recurrent or May 11, 2021 · Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

    Pembrolizumab Plus Concurrent Chemoradiation Therapy in

    Jun 04, 2021 · Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med . 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865 PubMed Google Scholar Crossref See Pembrolizumab plus chemotherapy approved for squamous The FDA approved pembrolizumab (Keytruda®) plus carboplatin and (nab-)paclitaxel for first-line metastatic squamous non-small cell lung cancer (NSCLC). Pembrolizumab plus chemotherapy effective in squamous Oct 07, 2018 · Standard first-line therapy for metastatic, squamous NSCLC is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] eion on 50% of tumour cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.

    Updated Analysis From KEYNOTE-189:Pembrolizumab or

    Mar 09, 2020 · Until the advent of immunotherapy, first-line treatment of patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) without an EGFR / ALK alteration was platinum-based chemotherapy, with addition of bevacizumab as an option in select patients. 1, 2 The introduction of pembrolizumab, an antiprogrammed death-1 (PD-1) monoclonal antibody, has altered the Pembrolizumab plus Chemotherapy in Metastatic NonSmall

    • TreatmentScopeAdministrationTrialAssessmentAnalysisResultsStatisticsPrognosisAdverse effectsSociety and cultureFundingParticipantsPembrolizumab plus chemotherapy-induced pneumonitis in Methods:We conducted a 36-centre, retrospective cohort study in patients with chemo-naïve advanced non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed and pembrolizumab between December 2018 and June 2019. Results:The study comprised 299 patients. The most frequent grade 3 non-hematologic adverse event was pneumonitis.